div class=trans-pagebuttonPage 1button div class=trans-image amp-img class=trans-thumb alt=Page 1: oncologyproesmoorgTao 1671 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy src=https:reader030fdocumentsusreader030viewer20220408135e5868227ac70105366b9088html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 2button div class=trans-image amp-img class=trans-thumb alt=Page 2: oncologyproesmoorgTao 1671 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy src=https:reader030fdocumentsusreader030viewer20220408135e5868227ac70105366b9088html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 3button div class=trans-image amp-img class=trans-thumb alt=Page 3: oncologyproesmoorgTao 1671 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy src=https:reader030fdocumentsusreader030viewer20220408135e5868227ac70105366b9088html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 4button div class=trans-image amp-img class=trans-thumb alt=Page 4: oncologyproesmoorgTao 1671 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose scheme ± Chemo-therapy src=https:reader030fdocumentsusreader030viewer20220408135e5868227ac70105366b9088html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 5button div class=trans-image amp-img class=trans-thumb alt=Page 5: oncologyproesmoorgTao 1671 2016 Design Phase I Retrospective Retrospective I ntra-hepatic perihilar Intra-hepatic perihilar Number patients 10 26 risk RT dose...